Catalent flags problems at its manufacturing plants; CFO departs
Reuters
Published Apr 14, 2023 07:43AM ET
Updated Apr 14, 2023 02:41PM ET
(Reuters) - Contract drug manufacturer Catalent (NYSE:CTLT) Inc on Friday warned that slow production at three of its facilities will impact its fiscal 2023 results and said CFO Thomas Castellano has stepped down, sending its shares down more than 20%.
The company said it experienced "productivity issues" at its gene therapy manufacturing site in Harmans, Maryland after a slower-than-expected ramp up in production capacity and that it would affect its third- and fourth-quarter revenue.
Catalent also faced similar challenges at its facilities in Bloomington, Indiana and Brussels, Belgium that the company said would impact its outlook and third-quarter results.
The company's shares fell 21.3% to $45.20, losing about $3 billion in market capitalization.
The company makes drug substances as well and finished drug products for manufacturers. Its larger clients have included companies such as Moderna (NASDAQ:MRNA) Inc and Johnson & Johnson (NYSE:JNJ).
Catalent is currently the sole contract manufacturer for Novo Nordisk (NYSE:NVO)'s highly popular weight loss drug Wegovy, which uses the same ingredient as its diabetes drug Ozempic.
Novo Nordisk, which was overwhelmed by demand for Wegovy after it was launched in the United States in 2021, said on Thursday that a second contract manufacturer was ready to begin production of the drug.
It was not immediately clear if Wegovy was made at any of Catalent's impacted facilities. Novo Nordisk was not immediately available for comment outside of business hours.
Catalent on Friday also named company insider Ricky Hopson as interim CFO and said it had launched the search for a permanent finance chief.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.